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Lipids are integral cellular components that act as substrates for energy provision, signaling molecules, and essential
constituents of biological membranes along with a variety of other biological functions. Despite their significance, lipid
accumulation may result in lipotoxicity, impair autophagy, and lysosomal function that may lead to certain diseases and
metabolic syndromes like obesity and even cell death. Therefore, these lipids are continuously recycled and redistributed by
the process of selective autophagy specifically termed as lipophagy. This selective form of autophagy employs lysosomes for
the maintenance of cellular lipid homeostasis. In this review, we have reviewed the current literature about how lipid
droplets (LDs) are recruited towards lysosomes, cross-talk between a variety of autophagy receptors present on LD surface
and lysosomes, and lipid hydrolysis by lysosomal enzymes. In addition to it, we have tried to answer most of the possible
questions related to lipophagy regulation at different levels. Moreover, in the last part of this review, we have discussed
some of the pathological states due to the accumulation of these LDs and their possible treatments under the light of
currently available findings.
1. Autophagy: A Brief Overview
Autophagy is a conserved intracellular degradative process
conserved from very simple organisms (yeast) to highly
complex animals (mammals). This process begins with the
formation of a double-membrane cup-like structure named
phagophore in response to stress circumstances (i.e., nutri-
ent scarcity). In the subsequent step, autophagosome is
formed as a result of an extension of the phagophore,
sequestrate of cytoplasmic contents/organelles, and finally,
the closure of both ends. Afterward, the resultant auto-
phagosome is fused with the lysosome to form an autolyso-
some to finally break down the desired substance (Figure 1)
[1–3]. Autophagy is not only important for supplying energy
to starving cells; instead, it is very crucial for the smooth
physiological integrity of the cells. Autophagy-defects or
deficiency may result in several ailments including neurode-
generative disorders, cardiac diseases, diabetes [4, 5], repro-
ductive abnormalities, and even infertility [6].
The research on autophagy progressed with an outstand-
ing pace, and to date, an ample number of autophagy-related
(Atg) genes (more than30)havebeen identified.Thereare four
key events involved in autophagosome formation: (1) initia-
tion: translocation of uncoordinated 51-like kinase 1 (ULK1)
complex upon the mammalian target of rapamycin (mTOR)
results in class III phosphatidylinositol 3-kinase (PI3K) activa-
tion that ultimately helps in phosphatidylinositol 3-phosphate
(PI3P) formation and PI3P-binding proteins recruitment at
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the site of autophagosome formation. (2) Vesicle nucleation:
Atg9L1 (a transmembrane protein) is involved in the nucle-
ation event of the autophagosomal membrane. (3) Auto-
phagosome formation: this event involved the conjugation
of C-terminus of microtubule-associated protein 1A/1B-
light chain 3 (LC3) with phosphatidylethanolamine (PE)
for anchoring of the protein in the membrane and is medi-
ated by a ubiquitin-like system (Atg7, Atg3, and the
Atg12–Atg5–Atg16L1 complex). (4) In the final step, the
isolated membrane is elongated and degraded to help the
fusion of this autophagosome with lysosome [3, 7, 8].
2. Selective Autophagy
Autophagy triggered by food restriction was formerly consid-
ered to be a nonselective process, but a growing body of data
suggests that it is, since autophagy selectively targets a variety
of cargos, including organelles and protein aggregates
(Figure 1). “Autophagy cargo receptors” are the main players
of selective autophagy as they bind with the targeted mate-
rials having degradation signals (ubiquitin) via ubiquitin-
binding domain (UBD). In mammals, the presence of an
LC3 interacting region (LIR) motif equips these receptors
with a unique property to interact with LC3 (Atg8) present
on newly formed autophagosomes. As a result, by serving
as molecular bridges, these autophagy cargo receptors desig-
nated the targeted compounds, tagged with a ubiquitin tag,
for destruction by autophagy or the ubiquitin proteasome
system (UPS). These receptors, such as p62/ SQSTM1,
NBR1, and histone deacetylase 6 (HDAC6), support the
removal and destruction of protein aggregates via UBD and
LIR2 in aggrephagy (a form of selective autophagy) [3,
7–10]. Despite the lack of orthologues of UBD-containing
adaptor proteins (p62) in yeast, mass spectrometric studies
recently assisted in the identification of Cue5, which is likely
a possible autophagy cargo receptor [11]. There is a coupling
of ubiquitin conjugation to ER degradation (CUE) domain in
yeast Cue5 (similar to UBDs in mammals) that can interact
with Atg8 and binds to ubiquitylated targets. Therefore,






























Figure 1: Bulk autophagy vs. selective autophagy: autophagy is a natural intracellular catabolic activity that helps cell in the removal of
unwanted substances and recycling of cellular components while selective autophagy selectively target several specific cargos including
various organelles, cellular substances, and protein aggregates.
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cargo via selective autophagy by acting as an ubiquitin–Atg8
adaptor protein (analogous to p62 in mammals). Yeast Cue5
and TOLLIP (mammalian orthologue) both aim to remove
aggregation-prone proteins (i.e., huntingtin), unable to
degrade via UPS, by autophagy (K. [11]). Besides the removal
of protein aggregates, selective autophagy also helps in the
clearance of damaged organelles (Figure 1). For instance,
selective autophagic degradation of worn out and superflu-
ous mitochondria is specifically named as mitophagy [12,
13]. Similarly, the degradation and removal of peroxisomes
are known as pexophagy [14, 15]. In mammals, LC3-
positive phagophores are recruited, by p62 and NBR1
(autophagy cargo receptors), to the surface of targeted mono-
ubiquitylated peroxisomes [16, 17]. Besides mitophagy and
pexophagy, selective autophagy can be categorized into vari-
ous types depending upon the specific cargos to be targeted,
i.e., aggrephagy, xenophagy, glycophagy, reticulophagy, ribo-
phagy, nucleophagy, zymophagy, and lipophagy. Unlike
mitochondria and peroxisomes, the detailed insight of
molecular mechanism and the role of selective autophagy in
the clearance of other organelles need to be elucidated.
Intriguingly, ER degradation in yeast seems to be accom-
plished via microautophagy but in fact, no microautophagy
machinery is involved in this process [18]. Moreover, large-
sized macromolecules like iron complexes and lipids can also
be degraded by selective autophagy. Similarly, several inter-
mediary macromolecular species, i.e., inflammasome, mid-
body, and midbody ring, are also targeted by selective
autophagy [19–22]. However, the only lipophagy will be dis-
cussed in the rest of this review.
3. Lipophagy: A General Overview
There is a battery of powerful hydrolytic enzymes in lyso-
somes including glycases, nucleases, proteases, and lipases
that are responsible for a rapid turnover of unnecessary cell
components [23]. Molecular basis of how cellular fat stores
are regulated in lipid droplets (LDs) remains a hot topic in
the past few years [24]. Cells tend to store the surplus energy
in the form of fats, during nutrient-rich status, within special
cytoplasmic structures called LDs that act as a vast depot of a
variety of molecules such as esters, cholesteryl esters, neutral
lipids, and triglycerides [25]. These LDs are encircled by a
variety of coat proteins (generally perilipins family proteins
(PLINs)) and a single layer of phospholipids [26]. These
fat depots are often regarded as distinct organelles because
of their ability to neutralize the effects of infectious entities
[27] and misfolded proteins [28] and also because of their
dynamic interactions with other cytoplasmic organelles
[29]. LDs are manufactured at ER and generally range in size
from 0.1 to 10μm in most of the cell types [25, 30]. How-
ever, LDs found in adipocytes (fat storage cells) may attain
a much larger size than average and grow up to 100μm in
size [31].
Starvation stimulates lipids to break down in a process
named as lipolysis (Figure 2) by protein kinase A activation
that results in phosphorylation of PLIN1 (LD coat protein)
[32]; this phosphorylation helps in degradation of PLIN1
by proteasomal activity that recruits cytosolic lipases to
LDs [32]. The autophagolysosomal system was postulated
to be implicated in the destruction of LDs during starvation
because nutritional shortage causes autophagy activation,
which supplies nutrients by breaking down worn out and
unneeded cytoplasmic material via lysosomal degradation.
Hepatocytes were either chemically treated with an autoph-
agy inhibitor (3-methyladenine) or autophagy was inhibited
using small hairpin (sh) RNA against Atg5 to test this
hypothesis. Following that, in both situations of autophagy
failure, a substantial rise in LD content was found [22].
Moreover, an increased level of triglyceride was also
observed in autophagy-deficient mouse embryonic fibro-
blasts [22]. Further studies employing mitochondrial β-oxi-
dation and rates of triglyceride breakdown revealed this
increase in lipid contents was a result of decreased lipid
turnover in autophagy-deficient cells instead of an increased
triglyceride synthesis. In addition to it, sequestration of LDs
by LC3 (autophagy marker)-labeled autophagosomal mem-
brane was confirmed using immunogold electron micros-
copy. Subsequently, in the starved liver, the presence of
LC3, PLIN1, and PLIN2 was also confirmed in LDs and
lysosomes [22]. Furthermore, the colocalization of LDs and
lysosomes indicated the significance of the lysosomal degra-
dation system in LD catabolism [22]. As autophagosomes
were found to engulf LDs and subsequently fused with lyso-
somes, lipophagy is regarded as selective macroautophagy
(macrolipophagy) involved in LD breakdown (Figure 2). In
line with these findings, selective Atg7-knock out in the liver
resulted in increased LD contents in vivo and was compara-
ble to nonalcoholic fatty liver disease (humans) histologi-
cally [22]. Interestingly, the acute supply of lipids (oleic
acid) was found to trigger lipophagy in hepatocytes [22].
Lipophagy (autophagy) activation is perhaps an ubiquitous
response against a sharp lipid influx as observed in various
cell types. For instance, similar response to eliminate the
excessive lipid contents was also observed in cultured hypo-
thalamic neurons treated with oleic acid [33]. In contrast to
the acute supply of lipids, chronic lipid supply showed an
opposite trend, and suppression of lipophagy was observed
in mice obesity models (both genetic and diet-fed models)
and led to ER stress and hepatic inflammation upon pro-
longed high-fat-diet feeding [22]. In line with it, ATG7-
overexpression successfully reversed hepatic LD accumula-
tion and prevented steatosis in obese mice [34]. The results
of all these studies are suggestive of an important role of
lipophagy (autophagy) in LD turnover. However, an out-
standing question that what causes the autophagic flux to
decrease under over nutrition conditions remains to be elu-
cidated. Multiple mechanisms are speculated to be involved
in decreasing the autophagy in obesity. Previously, in vivo
assay showed a 70% decrease in the fusion of autophago-
some with lysosome in a high-fat diet mice model [35]. Sim-
ilarly, a significant decrease in autophagolysosomal fusion
was also noted in alcohol-induced hepatotoxicity [36].
Besides lysosomal pH and ATP availability, few dietary fac-
tors also affect autophagolysosomal fusion activity by alter-
ing the lipid composition of the lysosomal membrane [35,
37]. The first report describing autophagy contribution in
hepatic LD turnover threw into gear a new chapter of
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research, and since that time, a plethora of studies have now
identified lipophagy as the main player involved in LD
breakdown in a variety of cells, i.e., adipose-resident macro-
phages [38], prostate cancer cells [39], orexigenic hypotha-
lamic neurons [33], lymphocytes [40], cultured adipocytes
[41], macrophage foam cells [41–43], primary striatal neu-
rons, glial cells [44], and gastrointestinal epithelial cells
[45]; in nonmammals, i.e., yeast [46, 47], fungus [48], and
worms [49, 50]; in plants including rice [51]; and also in
phyllosphere microorganisms [52]. Therefore, these findings
are enough to support the use of term macrolipophagy/lipo-
phagy as an ubiquitous pathway responsible for LD mobili-
zation [22].
Lipophagy is a highly regulated process; recently, autoph-
agy was found to be regulated by SNARE (soluble N-ethyl-
male-imide-sensitive factor-attachment protein receptors)
proteins that do so by facilitating the recruitment of ATG
proteins to autophagosomal formation sites [53, 54]. SNARE
protein syntaxin-17 has also been reported to regulate
























Figure 2: Major pathways in LD degradation: CMA facilitates LD degradation by promoting PLIN protein degradation allowing access for
lipases. Moreover, both microlipophagy and macrolipophagy also degrade LDs to generate free FAs that are utilized in mitochondria for
their complete oxidation.
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this protein is also involved in decrease of lipophagy/auto-
phagolysosomal fusion in obesity is still not known [53].
Moreover, membrane GTPases have been associated with
LD degradation as LDs were found to be significantly accu-
mulated in autolysosomes upon small GTPase dynamin-2
inhibition [55]. Recently, Bif-1 (a membrane curvature pro-
tein) has been identified as a novel protein regulating lipo-
phagy in adipocytes (Y. [56]). Lipophagy induced an
enhanced Bif-1-dependent PLIN1 breakdown, and its defi-
ciency ultimately reduced triacylglycerol (TAG) hydrolysis,
suggesting the significance of Bif-1 in lipophagy-dependent
PLIN1 degradation and subsequently LD catabolism (Y.
[56]). Interestingly, membrane curvature was shown to vary
with the size of the LDs; however, whether Bif-1 regulates
lipophagy via altering the size of the LDs is unknown at this
time. In fact, the processes that activate lipophagy may be
context-dependent and differ depending on the cell type.
These lipophagic processes are adapted by cells to cope with
severe conditions such as starvation and lipotoxicity. Despite
these differences in processes, it is assumed that the basic
machinery for lipophagic breakdown is conserved [57].
4. Mechanisms of Lipophagy Induction and Its
Molecular Machinery
4.1. PLINs and Lipases in Lipophagy Induction. Despite
variations in the size, composition, and location of LDs in
the cell, the best feature that better defines their dynamic
character is their proteome. On the surface of the LDs are
a number of proteins that control their signalling and meta-
bolization. One of these proteins’ characteristics is their par-
ticipation in the control of LD-related processes, particularly
lipophagy. The perilipin family of proteins is one of the best-
known protein families that affect LD activities and perform
many tasks in LD biology [58]. PLIN family comprised of
five members (PLIN 1-5) that share the varying degree of
homology and differs from each other in their activities
and tissue expression profiles. PLINs are capable of modu-
lating the access of lipases to LD surface, hence regulating
the LD metabolism [58]. It has been recently reported that
PLINs are the major molecules that may link chaperone-
mediated autophagy (CMA) to LD catabolism [59]. All of
these investigations have described the accumulation of
LDs upon lysosome-associated membrane protein 2A
(LAMP2A) degradation which is an important protein
involved in CMA. Moreover, to promote CMA-mediated
breakdown in lysosomes, the binding of the heat shock cog-
nate protein of 70 kDa (Hsc70) to CMA recognition motif
(KFERQ) within PLIN2 and PLIN3 was observed
(Figure 2). Reduction of lipophagy and lipolysis mediated
by lipases was found to be decreased upon CMA ablation
and is suggestive of the significance of PLIN2 and PLIN3
degradation in promoting LD catabolism and in allowing
access of adipose triglyceride lipase (ATGL) and other
autophagic proteins to LD surface. Further investigation
helped in the identification of a vital protein named AMP-
activated protein kinase that is involved in CMA-mediated
degradation of phosphorylated PLIN2 [60]. As a result of
these findings, it can be inferred that PLIN degradation
through CMA is an upstream process necessary for lipo-
phagy start. The importance of ATGL in the catabolism of
TAG during the degradation of PLINs may also be deduced
from the aforementioned explanation. More in-depth
research later revealed a strong connection between autoph-
agy (lipophagy) and ATGL. For instance, a direct interaction
between LC3 and ATGL has been demonstrated on the LD
surface [61] along with LC3 interactions with HSL. This
interaction between LC3 and ATGL occurs at LIR residues
145-150 (STFIPV). LIR depletion caused a deficiency in
ATGL localization and translocation to the LD surface dur-
ing hunger. These findings point to LC3 playing a crucial
role in TAG hydrolysis by transporting ATGL to the LD sur-
face. However, it is uncertain why ATGL requires LC3 for its
localization to the LD surface.
According to the studies carried out to date, it can be
perceived that both ATGL and lipophagy contribute directly
to LD catabolism (Figure 2). Sathyanarayan and colleagues
have recently described if there any linearity exists between
ATGL and autophagy/lipophagy [62]. ATGL was found to
promote the interactions of LC3 and lysosomes with LDs
and positively regulates autophagic flux in the liver suggest-
ing enhanced lipophagy. Intriguingly, the effects of ATGL
overexpression on LD breakdown were diminished as a
result of lysosomal acid lipase (LAL) degradation or genet-
ic/chemical inhibition of autophagy. ATGL was previously
shown to promote SIRT1 (an important autophagy player)
activity [63, 64], and SIRT1 was also found to mediate the
effects of ATGL in endorsing autophagy (lipophagy). Fur-
thermore, we recently reported on Sirt1’s function in testos-
terone production via autophagy control in the LC3-
dependent pathway. Sirt1 promotes autophagosome produc-
tion by deacetylating LC3 in the nucleus of leydig cells.
NHERF2 is degraded by autophagosomes, which increases
the expression of SR-BI. By increasing cholesterol absorp-
tion, SR-BI speeds up testosterone biosynthesis [65].
Subsequently, autophagy (lipophagy) was found to be
increased by PNPLA5 and PNPLA8 (two members of ATGL
(PNPLA2) containing family) in the variety of cell types [66,
67]. It has been described that diacylglycerol produced by
PNPLA5 is involved in the synthesis of autophagosomal
membranes, hence regulating protein trafficking by influenc-
ing membrane curvatures. Concluding the above results, it
can be interpreted that lipases including ATGL regulate
autophagy (lipophagy) and the resultant lipophagy mediates
bulk degradation of LDs. It is noteworthy that impaired lipo-
phagy and normal macroautophagy observed in macro-
phages lacking ATGL are indicative of the existence of cell-
type-specific function [68]. Although lipolysis is tightly reg-
ulated via multiple signaling pathways (cAMP/PKA, AMPK,
etc.) and a vast variety of proteins influence it via direct
interaction with ATGL or other LD proteins, much remains
to investigate about how lipophagy is regulated via ATGL-
mediated signaling.
4.2. Rab GTPases in Lipophagy Induction. Many Rab pro-
teins have been known to play critical roles in LD metabo-
lism and LD biology since the time of their discovery
[69–72]. Around 70 members of Rab family GTPases are
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thought to regulate endosomal membrane trafficking via
conferring a special “identity” to trafficking items [73]. Rabs
serve as molecular switches, cycling between active (GTP-
bound) and inactive (GDP-bound) states. By controlling
the connections between membrane fusion complexes and
cytoskeletal components, this interconversion is critical for
enabling the complicated intracellular vesicular traffic
(motor proteins). The discovery of over 30 Rab GTPases
on the surface of LDs has sparked a fresh wave of research
into their role in LD catabolism [74]. An impaired lipo-
phagy, characterized by a pronounced decrease in LD turn-
over, was observed upon the ablation of several members
of the GTPases family. Rab7 is an important player in autop-
hagosomal maturation [75, 76] and intracellular trafficking
(a marker of the endocytic pathway) [77], one of those Rabs
that concentrate on LD surface. Rab7 facilitates the interac-
tions between components of HOPS tethering complex and
numerous SNARE proteins hence promote the fusion of
endocytic and autophagic membranes [78, 79]. Moreover,
Rab7, along with several downstream effector components
including FYVE, FYCO1, and RILP, mediates organelle
transport (both plus- and minus-end directed) in tight coop-
eration with kinesin and dynein-dynactin motors [80–82].
Therefore, Rab7 is thought to play a prime role in mediating
interactions among many cell components and actively
contributes to promoting versatile biological activities such
as autophagy (lipophagy). Interestingly, Rab7 has also been
found to play an important role in mitophagy where it
facilitates the encapsulation of mitochondria within auto-
phagosomes with the help of TBC1D15 and TBC1D17
(two significant GTPase-activating proteins) [83]. Rab7’s
enhanced colocalization with LDs, lysosomes, and autopha-
gosomal membranes led to the discovery of Rab7’s impor-
tant involvement in LD homeostasis for the first time [84].
Rab7-knockdown via siRNA or a negative form of Rab7 in
hepatoma cells led to an abnormal LD accretion [85]. Dur-
ing starvation, Rab7 facilitates the priming of LDs by
increasing GTP affinity than GDP and recruiting the degra-
dative machinery to LD surface by directly activating on LD
surface [86]. The findings of this study point to Rab7’s
importance in regulating hepatic lipophagy by serving as
an LD-localized node. Rab7 has recently been linked to
ethanol-induced hepatic steatosis as well [87]. Rats on an
alcohol-rich diet were found to be resistant to starvation-
induced lipophagy and developed hepatic steatosis as a
result. Rab7 levels were substantially lower in hepatocytes
treated with alcohol compared to controls, indicating an
autophagic failure in LD detection. Furthermore, more
research is needed to determine the specific mechanism
behind the inhibition of lipophagy in ethanol-exposed hepa-
tocytes. Rab10, which is found on the surface of LDs, is
another member of the Rab family that may play a role in
lipophagy. This Rab member regulates Golgi trafficking dur-
ing epithelial polarization [88] and insulin-stimulated
GLUT4 vesicular trafficking [89]. Furthermore, in a recent
report, Rab10 has been found to play a key role in ER mor-
phogenesis by regulating tubular extension and fusion [90].
Rab10 depletion or genetic ablation also led to an increased
LD accumulation in hepatoma similar to Rab7 [91]. In
starved cells, there was an interesting translocation and colo-
calization of Rab10 (activated) with autophagic membrane
markers such as LC3 and Atg16 on the LD surface. Rab10
may enhance LD envelopment by increasing phagophore
via EH domain-binding protein 1 and 2 (membrane-
deforming ATPase) functioning in a complex downstream
of Rab7 during lipophagic development; it was hypothesized
[91]. Although other members of the Rab family have also
been associated with lipolysis and LD metabolism, however,
their putative roles in LD selective autophagy are largely
unknown. Colocalization of Rab32 with LD and autophagic
membrane markers have also been reported in the fat body
of Drosophila [92]. Furthermore, an increased ATGL level
and the decrease in number and size of LDs was found upon
Rab32-knockdown [93]; however, how ATGL expression
was increased remains unidentified and need more in-
depth studies. Another member of GTPases known to con-
tribute in LD homeostasis is Rab18. Rab18 was found tightly
associated with LD surface and found to influence adiposity
[94]. Upon β-adrenergic stimulation, most of this small
GTPase (Rab18) was exclusively found to localize at LD sur-
face [95, 96]. Rab18 binding to only a subset of LDs indicates
a distinct recruitment pattern that is dependent on the met-
abolic state of the LDs. Interactions between the proteins
COP-I and TRAPP-II aid in the relocalization of TRAPP-
II on the surface of LDs and enhance lipolysis by activating
Rab18 [97]. TRAPP complexes have been described to par-
ticipate in autophagy [98]; hence, there is a need to carry
out further investigations to explore any possible role of
Rab18-TRAPP interactions in lipophagy. In addition to
these studies, Rab25 have been recently identified in hepatic
stellate cells (HSCs) to contribute in autophagy of LDs
enriched in retinyl ester (Z. [99]). The increase in Rab25
expression was assumed to be caused by the release of reac-
tive oxygen species (ROS) as a result of HSC activation.
Rab25-ablation by siRNA led in LD turnover being reduced,
which inhibited HSC activation. These findings point to a
new role for Rab25 in lipophagy; however, it is unclear if this
GTPase works just on the surface of LDs or impacts other
autophagic arms.
4.3. LD-Surface Receptors in Lipophagy. Identifying the
receptors involved in cargo-specific selective autophagy has
been of significant interest in revealing the link between a
particular organelle and autophagic machinery [9]. With
the exception of LDs, these unique autophagic receptors
have been identified in nearly all organelles. The majority
of these receptors were discovered to interact with LC3B
via LIR, as previously reported [100]. For example, the dis-
covery of NDP52 and optineurin (two of the most essential
mitochondrial cargo receptors) provided fresh and interest-
ing insights into mitophagy [101, 102]. NDP52 may partici-
pate in other types of autophagy (i.e., xenophagy) [103, 104]
while there are several other general candidate receptors
such as p62/ SQSTM1, NBR1, and Huntingtin that play
important roles in targeted turnover of several other organ-
elles [16, 105, 106]. Furthermore, significant accumulation of
LDs as a result of a mutation in Huntingtin is suggestive of a
critical role of this receptor protein in LD metabolism [106,
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107]. Because LC3-binding to ATGL promotes LD degrada-
tion, no additional LD-resident proteins that unequivocally
mediate lipophagy via an LC3-binding mechanism have
been discovered yet. These findings point to other proteins
(such as Rab7 and others) recruiting autophagic machinery
via an as-yet-unidentified mechanism. Protein changes such
as polyubiquitination are an alternate method for promoting
lipophagy. For example, ancient ubiquitous protein 1
(AUP1) can be marked for destruction by interacting with
Ube2g2 via its G2 binding domain (E2 ubiquitin conjugase
G2) [108–110]. To understand the details of how this signal-
ing is initiated and how it helps in regulating LD turnover
via autophagy required more rigorous investigations on this
front in the near future.
5. Lipophagy Regulation
5.1. Transcriptional Regulation. Over the last few decades,
considerable progress has been made in understanding
autophagy and, to a lesser degree, lipophagy regulation at
the transcriptional level. Microphthalmia-associated/TFE
subfamily of basic/helix-loop-helix/leucine zipper transcrip-
tion factors, including HLH-30 (C. elegans) and TFEB and
TFE3 (mammals), are the most researched autophagy/lipo-
phagy regulators among all of these transcriptional regula-
tors. TFEB has been discovered to enhance lipophagy as
well as contribute to fat metabolism by activating PPAR-
coactivator 1 (PGC-1) and PPAR-targeted genes that govern
fat catabolism [111]. Lipophagy and lysosomal-associated
lipolysis were observed as a result of coordinated TFEB
homolog HLH-30 activation that does so by enhancing the
expression of many lysosomal lipases in C. elegans [50].
Moreover, starvation-induced LAL expression was found to
be TFEB dependent in mice. In addition to it, TFE3 has also
been found to regulate hepatic lipophagy. It is of great inter-
est that steatosis was observed upon hepatic ablation of
TFE3 while hepatic overexpression of TFE3 resulted in a
decrease of steatosis via lipophagy induction [112]. TFE3
overexpression in adipocytes, on the other hand, was shown
to increase obesity [113], which may be explained based on
current research showing the important role of autophagy
in adipocyte development ([114, 115]; C. [116]). These stud-
ies are suggestive of differential regulation of lipid metabo-
lism by TFE3 in adipocytes and liver. Lipophagy induction
and LAL expression were noted in adipose tissue as a result
of starvation-induced activation of FOXO1 [41]. Further-
more, hepatic steatosis and hypertriglyceridemia were
observed in liver-specific FOXO 1/3/4 knockout mice while
overexpression of ATG14 resulted in a reversal of these
anomalies [117]. In a similar research, cAMP response
element-binding protein (CREB) was found to enhance lipo-
phagy under deprivation by activating the TFEB, but food
supplementation reversed these circumstances via farsenoid
X receptor activation (FXR) [118]. Moreover, PPAR-α
activation under nutrient depletion was found to inhibit
FXR-mediated lipophagy suppression (J. M. [123]), and the
results of this study speak about a regulatory interaction
between FXR and PPAR-α. Based on these findings, it can
be concluded that starvation-induced activation of certain
transcription factors and coactivators such as TFEB, TFE3,
PPAR-α, PGC-1α, FOXO1, and CREB is involved in pro-
moting while nutrient supplementation-induced transcrip-
tion factors, such as FXR, are involved in suppressing
lipophagy. Recently, it was shown that the sterol response
element-binding protein-2 (SREBP-2) is also involved in
autophagy/lipophagy control. SREBP-2 knockdown acti-
vates autophagy and increases LD turnover by increasing
autophagosome formation in the presence of sterol depriva-
tion [119]. In addition to it, SREBP-2 was found to prevent
liver steatosis by promoting lipophagy via enhancing the
expression of PNPLA8 [67]. Therefore, based on these find-
ings, it can be concluded that SREBP-2 compensates choles-
terol deficiency not only by promoting lipophagy but also by
directly increasing the biosynthesis of cholesterol by pro-
moting the expression of the relevant genes. Furthermore,
these studies throw the light on the significance of lipid sig-
naling in lipophagy regulation.
5.2. Nutritional and Hormonal Regulation. Various mecha-
nisms that respond to the nutrient status of cell also regulate
lipophagy, such as mTOR (H. [120]), AMPK (Y. [121]),
farnesoid X receptor (FXR), and peroxisome proliferator-
activated receptor-α (PPARα) (J. M. [122]). mTOR is
engaged in a variety of activities, including the control of
several downstream metabolic processes. It is also known
as the major signalling hub since it reacts to a variety of hor-
mones, including insulin, as well as nutrients like glucose
and amino acids. It is a strong autophagy inhibitor that is
activated in response to nutrition. When rapamycin was
used to block mTOR via autophagy activation, enhanced
lipid oxidation and catabolism were found (mTOR inhibi-
tor) [123]. In addition to it, LD turnover was observed to
be increased in hypothalamic neurons upon autophagy
induction via serum deprivation that inactivates mTOR by
decreasing its phosphorylation [33]. Moreover, the interplay
between the autophagic process and lipolysis via mTOR
inhibition has been described in an outstanding study car-
ried out in worms [49]. Interestingly, rapamycin was found
to increase the lifespan of C. elegans via enhancing the activ-
ity of lysosomal lipase lipl-4. Therefore, it can be concluded
that mTOR similarly regulates lipophagy and autophagy;
however, how it suppresses lipophagy that remained largely
unknown?
It is of great interest that hormones that are usually
involved in catabolism also contribute to promoting lipo-
phagy. For instance, β-adrenergic signaling was found to
enhance the lipophagic process in adipose tissues similar to
hepatocytes [85] in a Rab-7-dependent manner [84]. Thyr-
oidine (T3) is another important hormone whose role in
hepatic mitochondrial β-oxidation and LD catabolism has
been well studied. Moreover, the presence of functional thy-
roid receptors was found to be necessary for LD turnover via
autophagy (Rohit Anthony [124]). However, how lipophagy
is regulated by T3 in extrahepatic tissues requires further
more detailed investigations?
Furthermore, lipophagy activation by oleic acid is sug-
gestive of lipophagy regulation by lipids themselves [22].
This activation of lipophagy was thought to be a cellular
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response to eliminate the influx of excess lipids. Intriguingly,
Kaushik et al. [33] reported similar findings in hypothalamic
neurons as a result of oleic acid treatment, suggesting this
response as a ubiquitous effect observed in numerous cell
types [33]. On contrary to acute supplementation, chronic
fat supplementation resulted in steatosis characterized by
low LC3 level in LDs, and a reversal of these circumstances
was observed upon hepatic ATG7 restoration (L. [34]).
Furthermore, chronic fat supplementation was found to
decrease lipophagy by reducing LAMP-2A that subsequently
causes a reduction of PLIN2 degradation via CMA [125].
5.3. Lipophagy Regulation via Small Molecules. A vast vari-
ety of natural compounds modulate lipophagy. A polyphe-
nolic compound, abundantly found in green tea, named
epigallocatechin-3-gallate (also called EGCG) has been
observed to influence hepatic autophagy/lipophagy [126,
127]. Similarly, caffeine was found to protect fatty liver dis-
ease by promoting LD catabolism via lipophagic induction
[128]. Furthermore, a dietary polyphenol contained in the
peel of the bergamot citrus fruit (bergamot) was shown to
regulate hepatic steatosis. In the livers of rats given 50mg/kg
bergamot for three months, there was a better LD output as
well as increased interactions between autophagic machin-
ery and LDs [129]. Furthermore, other elegant studies
reported the protective role of red wine bioactive resveratrol
in decreasing the extent of hepatic steatosis via autophagy/-
lipophagy mediation (Y. [130]). In contrast to above-
described molecules that promote autophagy/lipophagy, tet-
randrine, a bisbenzylisoquinoline alkaloid, resulted in lipid
accumulation in the liver cell line by impairing the normal
autophagic process. Although a range of natural compounds
has been reported to modulate autophagy, however, whether
these compounds also regulate lipophagy is unknown
yet [131].
6. Lipophagy in Disease States
6.1. Lipophagy and Pathophysiology of the Liver. Lipophagy
is a key regulator of LD metabolism in hepatic homeostasis;
as a result, any disruption in its normal function can cause to
excessive lipid buildup or steatosis, which can manifest in
both alcoholic and nonalcoholic fatty liver disease (NAFLD)
[132]. Furthermore, lipophagy also modulates inflammation
and apoptosis, major characteristics of these ailments [133].
In the first-ever study of lipophagy, hepatic TG and choles-
terol level was found to be increased in hepatocytes of mice
with defective autophagy [18]. Aging, obesity, inflammation,
and nonalcoholic steatohepatitis all show similar deficits
defined by autophagy abnormalities (NASH). Autophagy
suppression resulted in a rise in steatosis in mice given a
methionine-choline diet, whereas autophagy activation
resulted in a significant decrease in steatosis [134]. Autoph-
agy activation by resveratrol was also observed to attenuate
the steatosis induced by this diet, suggesting a possible ther-
apeutic potential of this compound to treat NASH [135].
Alterations in lipids other than hydrolyze triglycerides
(TGs) may influence the autophagy in fatty liver disease.
For instance, an increased level of bioactive sphingolipid cer-
amide was found in the liver of Atg7-ko mice [136]. More-
over, an increase in de novo sphingolipid synthesis resulted
in an upregulated autophagy activity suggesting that LD
catabolism via autophagy activation consume excessive
LDs for liver lipid homeostasis. Similarly, ceramide was
found to be upregulated in several other ailments including
diabetes [137] and obesity [138], both of which are associ-
ated with steatosis development [139]; therefore, it can be
speculated that autophagy defect may be a leading cause of
pathologies related to altered sphingolipid contents. In
agreement with these investigations, knockdown of Atg14
([117]) or Tfeb-ko [111] resulted in the enhancement of
hepatic TG level. Moreover, autophagy enhancement in
obese mice via Atg7/Atg14 overexpression alleviated the ste-
atosis extent [34, 91]. Although there is a huge number of
studies in favor of alleviation of hepatic LD accumulation
by lipophagy, however, some mouse models showed no or
less steatosis upon autophagic defect [140, 141]. This incon-
gruity may be a result of differences in experimental setups
and animal models. It was suggested that lipophagy perhaps
replenish LDs with fatty acids (FAs) during starvation
in vitro, while lipids are removed from LDs by lipolysis
[142]. However, this study was conducted on fibroblasts
with low lipid content, which were not grown in a serum-
free medium but rather in a saline solution for a longer
period of time. As a result, study’s findings are unworthy
of consideration and remain unclear. As a result, in this cir-
cumstance, more comprehensive in vivo studies are needed
to determine whether lipophagy reduces hepatic damage
and steatosis in NAFLD patients. In acute ethanol-induced
in vitro and in vivo models of liver steatosis and damage,
LD degradation was revealed to be mediated via autophagy
[143]. ROS intermediates, produced as a result of acute alco-
hol consumption, were found to induce lipophagy [143].
Similar observations were found in mice fed on ethanol diet
or upon overexpression of CYP2E1 (prooxidant enzyme)
([144]). Furthermore, a lower level of the main antioxidant
glutathione in the liver of mice given an alcoholic diet, which
was further reduced when autophagy was inhibited, clearly
implies that autophagy plays a protective role against
chronic alcohol-induced damage. On the basis of the afore-
mentioned, it can be inferred that LD degradation via
autophagy protects against ethanol-induced liver damage
and oxidative stress in both acute and chronic forms. This
protective role may be a result of excess lipid removal that
acts as a substrate for oxidative stress or via ATP supple-
mentation generated as a result of free fatty acids (FFAs)
catabolism via lipophagy, that is, the possible mechanism
of resistance adopted by hepatic cells against oxidative stress
[145]. ATGL and hormone-sensitive lipase (HSL) are the
major factors responsible for the hydrolysis of triglycerides
in adipocytes. Though ATGL shows highest expression in
fat tissues, a lower level of activity is also found in several
nonadipose tissues. ATGL deficiency led to an enhanced
LD accumulation in liver and heart besides adipose tissues
in mice. However, ATGL is involved in varying degrees of
phospholipid hydrolysis while no hydrolysis of cholesteryl
esters was observed under various experimental conditions.
Furthermore, HSL is expressed normally at an extremely
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low level in liver, and there are no studies so far describing
an association between HSL and lipolysis in the liver. On
the other hand, a reversal of hepatic steatosis was observed
upon HSL overexpression ex vivo [146]. “Two-hit theory”
is the age-old and reliable model for the study of develop-
ment and progression of NASH ([147]; [148]). The first
strike is defined by the onset of fatty liver disease, followed
by the second hit, which is characterised by the accumula-
tion of reactive oxygen species (ROS), liver inflammation,
and mitochondrial dysfunction, all of which lead to NASH.
However, the exact mechanism by which autophagy medi-
ates the two-hit scenario for NASH development is yet
unknown. Lipophagy was initially discovered to prevent
excessive fat accumulation during the first hit [22]. Secondly,
autophagy helps in the elimination of ROS-producing mito-
chondria and maintaining ATP levels preventing the second
hit. TNF-α is an inflammatory molecule that mediates
hepatic injury, and it has been reported that Atg-7 deficiency
led to hepatic injury upon administration of common
hepatic toxicants including galactosamine combined with
LPS/galactosamine with TNF-α to mice [149]. Lipophagy
plays an important role in protecting hepatocytes against
lipotoxicity. SIRT3, a NAD+-dependent deacetylase, pro-
motes macroautophagy through AMPK-dependent path-
way, downregulates SCD1 to inhibit lipogenesis, and
activates LCAD to promote β-oxidation of fatty acids and
in this way mitigate lipotoxicity ([150]). Impaired lipophagy
is associated with advancement in NAFLD [151]. Recently,
another study conducted by [152] have reported that dietary
intake and exercise help in controlling NAFLD by enhancing
lipophagy. These therapies enhance lipophagy in liver by
downregulating Akt/mTOR/ULK1 pathways and upregulat-
ing AMPK/ULK1 pathways ([152]). Moreover, lipophagy
not only prevents hepatic lipotoxicity but also helps in
VLDL production by providing free fatty acids. In FFA-
deficient conditions, nearly 70% of secreted VLDL comes
from the TG degradation in hepatocytes; however, mecha-
nism of TG breakdown to make VLDL remains unclear
[153]. Moreover, autophagy inhibition resulted in reduced
fatty acid oxidation and VLDL production, and autophagy
activation led to an enhanced VLDL production [154, 155].
In human subjects, autophagy examination has always
remained a major restraint to truly find the extent of autoph-
agy defect in human NAFLD. In addition to it, the samples
need to be pretreated with lysosomal inhibitors to measure
autophagy flux and activity [156, 157]. Despite these con-
straints, correlative studies have provided evidence of the
contribution of autophagy in the prevention of NAFLD
development in humans. For instance, autophagy cargo
p62/SQSTM1 was found to be accumulated in liver sections
from expired subjects and in biopsy samples obtained from
subjects with severe steatosis [158, 159]. As a result, an
inverse relationship between autophagy and liver total lipid
concentration may be hypothesised. Furthermore, autoph-
agy inhibition by pharmaceutical drugs used to treat steato-
sis reinforces the link between steatosis and lipophagic
activity. For example, thymidine analogues (stavudine and
zidovudine), which are frequently used as antiretroviral
treatment, have been shown to reduce autophagy and may
be responsible for the elevated LD content in these patients’
livers [160]. On the contrary, steatosis development was pre-
vented by anticonvulsant carbamazepine which is capable of
activating autophagy. Recently, obesity and related lipotoxic
states have been found to inhibit autophagy perhaps due to
an increased cytosolic calcium level [161]. Moreover, this
calcium led to an impairment of autophagosome-lysosome
fusion [161]. To further dig out this finding, obese mice were
administered calcium channel blocker verapamil that
resulted in autophagy activation and decreased the LD accu-
mulation and in turn improved insulin sensitivity [161].
Collectively, these investigations from humans and mice
models speak about a major function of lipophagy in LD
homeostasis in liver and formulate the basis to fully under-
stand the molecular mechanisms responsible for lipid
metabolism mediated by lipophagy (autophagy) [162].
6.2. Lipophagy in Stellate Cell Activation and Fibrosis. Lipo-
phagy transforms stellate cells into matrix-producing myofi-
broblasts, resulting in fibrosis as a pathologic condition. In
their dormant condition, these stellate cells tend to accumu-
late more lipids, mostly in the form of vitamin A. During the
activation of stellate cells, these lipid reserves are digested. In
hepatic stellate cells, fibrotic stimuli were observed to
increase macroautophagy [163, 164]. Autophagy-defective
stellate cells were failed to activate, and restoration of activa-
tion potential upon FFA oleate supplementation is sugges-
tive of lipophagy-driven transdifferentiation upon substrate
supplementation to obtain energy required for their activa-
tion [163]. Moreover, a decrease in fibrotic extent was
observed in vivo in autophagy-deficient stellate cells [163].
Whether lipophagy is responsible for fibrosis in organs other
than the liver is still unknown; however, the prime impor-
tance of stellate cell activation in fibrosis development and
progression is suggestive of significant roles of lipophagy in
this cell that may be critical in some fibrotic disorders. Taken
into account the previously described role of lipophagy in
liver steatosis, fibrosis, and injury, it can be suggested that
autophagy may influence multiple hepatic features of
NAFLD affecting a variety of cells [165].
6.3. Lipophagy in Metabolic Disorders. The finding that
autophagy functions in adipogenesis have thrown in gear a
considerable interest in investigating whether any possible
association exists between autophagy and metabolic disor-
ders, i.e., obesity. A direct correlation was found between
autophagy level and fat depot size among human subjects
with varying degrees and types of obesity. Intriguingly, sig-
nificantly high autophagic activity was observed in omental
fat tissue samples from obese subjects, and as a matter of
fact, a further increase in autophagy extent was found in
obese individuals with insulin resistance [166]. In addition
to the functional involvement of autophagy in the differenti-
ation of adipose tissues during development, our findings
imply that autophagy may play a role in controlling the size
of adipose tissues and lipid homeostasis in adulthood. The
increase of autophagy prior to obesity-related morbidity sug-
gests that autophagy activation may be used as a defence
mechanism to deal with excessive cellular lipid levels.
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Autophagy’s effects and outcomes, on the other hand, might
vary depending on metabolic status. For example, mTOR
attenuation has recently been reported in adipocytes from
type 2 diabetes patients, and this discovery lends credence
to the idea that this might be the mechanism behind autoph-
agy increase in these cells. As a result of the accelerated pro-
duction of LDs and their increased autophagic activity,
excessive FFA is released from LDs, posing cellular toxicity.
In these cases, autophagy blockage or autophagy decrease
may be a preferable technique [167]. Lipophagy has been
put forward recently as a probable defensive strategy to pre-
vent atherosclerosis resulting from atypical lipid amassing in
macrophage foam cells [168]. Furthermore, lipolytic LD
mobilization in foam cells mediated by autophagy was also
proposed as a potential mechanism responsible for athero-
genesis. Lipid loading resulted in an increased macrophage
lipophagy both in vitro and in vivo, and an abnormal choles-
terol removal was observed upon autophagy defect in mice
[42]. It can be speculated based on these findings that higher
concentrations of these circulating lipids may impair the
autophagic activity of macrophages and resulting in intracy-
toplasmic lipid deposits transform them into “foam cells”
[35]. The subsequent lipid deposition is the seeding to favor
atherosclerotic plaque development. Therefore, present ther-
apeutic attempts are targeting macrophages to reduce the
extent of lipid buildup in the form of endothelial plaques
by favoring the cholesterol efflux from them. Consequently,
interventions aimed at promoting autophagy and enhancing
cholesterol efflux are promising therapeutic tools in the cure
of atherosclerosis. Interestingly, the potential of arterial
smooth muscle cells may also be utilized in the manipulation
for autophagy upregulation to reduce arterial plaque forma-
tion. Furthermore, the inflammation associated with plaque
formation is a consequence of the compromised autophagic
activity of these cells [169].
6.4. Lipophagy in Aging and Longevity. The autophagy pro-
cess was found to be declined in many of the tissues and
organisms as the aging process goes on [170]. This decrease
in autophagy, particularly lipophagy, resulted in the buildup
of LDs, and the resulting large lipid depots exacerbated the
situation by further impeding the autophagic process,
favouring a path for the metabolic syndrome of ageing via
a potential feedback loop. Massive lipid accumulation in
organs, hypercholesterolemia, and insulin resistance are all
symptoms of the metabolic syndrome of ageing. Antilipoly-
tic medicines have demonstrated the ability to ameliorate
not just hypercholesterolemic conditions but also general
health span in mice models of ageing, which is of consider-
able interest [171]. However, their beneficial effects are
thought to be a result of autophagy induction in response
to increasing cytoplasmic lipid contents [172, 173]. Genetic
associations among autophagic process, longevity, and ath-
erogenesis have been found recently in C. elegans [49]. Func-
tional autophagy was found to activate LAL-4, and in turn,
this lipase showed a potential of autophagy induction. Inter-
estingly, the autophagic process and lipase need to work
together for lifespan extension upon germline elimination.
Though the particular target and how it affects autophagy
remains unknown, it can be speculated that it contributes
in longevity and lifespan extension by better handling of
cytoplasmic lipid contents via lipophagy [174]. Recent stud-
ies have found that unfolded protein response of the endo-
plasmic reticulum (UPRER) extend lifespan in an xbp-1s-
dependent manner [175] which is unregulated in response
to stress [176]. UPRER reverses onset of aging and extends
life span by two independent pathways. UPRER regulates
protein homeostasis via upregulating the expression of chap-
erones; on the other hand, it enhances depletion of lipid
droplets by promoting lipophagy via restructuring ER mor-
phology [177, 178]. Moreover, it has been found that dopa-
minergic neurons activate UPRER to drive lipid homeostasis,
and serotonergic neurons drive protein homeostasis by
upregulating UPRER. These two events in turn enhance lon-
gevity (Figure 3)
6.5. Lipophagy and Viral Replication. Removal of superflu-
ous cellular elements by autophagy is suggestive of its
involvement in the elimination of intracellular pathogens
[172]. In contrary to popular belief, certain infectious agents
may be able to manipulate this degradative route to their
advantage. Hepatitis viruses are the most common cause
of chronic hepatitis, and they modify autophagy in host
cells by an unknown mechanism. HCV causes an increase





























Figure 3: XBP-1s enhances longevity by promoting lipid and
protein homeostasis via two independent pathways mediated by
UPRER. XBP-1 induction promotes protein homeostasis via
chaperones and lipid homeostasis via restructuring ER. This
restructuring enhances lipophagic depletion of LDs.
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augmentation of autophagy helps in the replication of
viruses instead of their elimination. An association exists
between the HCV core proteins and LDs that helps in viral
assembly via an unknown mechanism [183]. Similarly,
autophagy augmentation has also found to enhance the rep-
lication of the dengue virus via the lipophagic mechanism.
LD-associated replication, similar to HCV, has also been
found in the dengue virus; however, the site of assembly
remains ambiguous [184]. It has been recently described
that autophagy may provide the energy required for viral
replication by metabolizing the lipids [185]. In hepatoma
cells, the dengue virus supported LD-coupled autophago-
some development. In infected hepatoma cells, lipophagy
resulted in an increase in -oxidation and a significant drop
in LD volume and TG. Furthermore, inhibiting autophagy
caused an increase in -oxidation levels, which halted viral
propagation. When FFA was added, the replication barrier
was removed, indicating that autophagic breakdown of
LDs resulted in the release of FFAs that were metabolised
by -oxidation to enhance viral replication. Replication of
HCV has also been shown to be dependent on β-oxidation
[185]. In hepatocytes, induction of lipophagy by these
viruses is a key event in the viral life cycle and may serve
as a potential novel therapeutic target for future therapies.
The exact mechanism involved in viral induction is still
unknown; however, NS4A has been identified as a potential
candidate involved in its induction [186]. Autophagy was
found to restrict the replication of dengue virus in mono-
cytes; therefore, it can be speculated that autophagy induced
by viruses may vary in other types of cells [187]. Moreover,
further investigations are required to explore whether lipo-















Figure 4: PRRSV infection promotes downregulation of NDRG1 and upregulation of Rab11a to promote replication: viral infection reduces
the expression of NDRG1 and enhances expression of Rab11a, both in turn promote lipophagy by inducing autophagy and enhancing
autophagosomes maturation respectively. Lipophagy promote viral replication by providing FFAs via LD degradation.
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the autophagic function such as HBV (K. [188]). According
to Wang et al. [189], PRRSV infection increases the expres-
sion of Rab11a at both the mRNA and protein levels.
Increased Rab11a expression promotes autophagosome
maturation, which leads to lipophagy. NSP2 and ORF7
expression was decreased when Rab11a expression was dis-
rupted. Rab11a silencing resulted in an accumulation of
LC3-II and p62, indicating Rab11a’s function in autophagy
surge. Furthermore, NSP2 and Rab11a were discovered to
be colocalized, indicating that Rab11a aids viral replication
by functioning as a proviral host factor (K. [189]). Recently,
it was found that downregulation of NDRG1 expression
promote PRRSV (Porcine reproductive and respiratory syn-
drome) replication by promoting lipophagy which in turn
increase the level of FFAs by increasing LD degradation
(Figure 4) ([190]).
7. Conclusion
Considering the facts described above, it can be inferred that
autophagy is engaged in the metabolism of a range of sub-
stances, with cytosolic lipids lately being added to the list
of targets. In the last decade, research on the function of
autophagy in lipid metabolism has advanced our under-
standing of how autophagy uses lysosomes to maintain lipid
homeostasis. The specific molecular processes of most of the
major activities involved in LD trafficking and catabolism, as
mentioned above, are, nevertheless, largely unknown.
Despite several studies, many unsolved issues remain,
including (1) how lipids are selectively directed towards
lysosomes? What are their molecular routes, exactly? (2)
How can lysosomes distinguish between different types of
lipids? (3) How does lipophagy break down particular lipid
species? (4) How is the equilibrium between various lipid
catabolic pathways maintained? (5) How can the integrity
and cross-talk between selective and nonselective LD break-
down through autophagy be maintained? Furthermore,
because the lysosome is the primary destination of autoph-
agy and other endocytic processes, identifying particular
proteins that regulate lipophagy might have therapeutic
implications. Because autophagy (lipophagy) dysfunction is
linked to a range of pathological disease states, additional
in-depth research to uncover the specific molecular pro-
cesses is recommended.
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